KLOTHO Therapeutics, Inc.

KTI, a virtual biotech company, has filed patents on modified KLOTHO proteins with great potential to positively impact aging, cognition, kidney function, fibrosis and cancer. KTI is well positioned to enter human trials within 2 years focused on its first indication: acute kidney disease, which kills 300k/year and represents a $2B market opportunity in U.S. alone. Led by successful biotech startup execs, KTI has de-risked the development process to accelerate human proof of concept studies

by